The Supreme Court has directed the Centre to consider constituting a committee to examine the practice of pharmaceutical companies offering gifts, incentives and other benefits to doctors to influence the prescription of their medicines.
A Bench of Justices Vikram Nath and Sandeep Mehta was dealing with concerns over the existing regulatory framework governing pharmaceutical marketing practices and whether stronger statutory safeguards are required to prevent unethical inducements in the medical sector.
The Court’s intervention comes amid allegations that pharmaceutical companies use various forms of incentives to encourage medical practitioners to prescribe their products. The issue raises concerns not only about professional ethics but also about the financial burden such practices could potentially impose on patients.
The Bench was informed about the Centre’s proposal to constitute a three-member panel to examine the issue comprehensively and assess whether the present regulatory mechanism is adequate or requires statutory backing.
The proceedings have also brought renewed focus on the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which lays down guidelines governing interactions between pharmaceutical companies and healthcare professionals.
The petitioners have contended that a voluntary or non-statutory regulatory framework may not be sufficient to effectively check violations. They have sought a stronger mechanism capable of imposing meaningful consequences where pharmaceutical companies provide inducements for promoting their products.
The Supreme Court has previously examined the need for greater accountability in the pharmaceutical sector and questioned whether the existing framework provides an effective means of enforcing restrictions on promotional practices.
The larger issue before the Court is whether commercial interests of drug manufacturers can be permitted to influence medical prescriptions and, consequently, the treatment choices and expenditure of patients.
The proposed committee is expected to examine the existing regulatory regime, identify gaps in enforcement and make recommendations on the need for a statutory framework governing pharmaceutical marketing practices.
The matter assumes significance in the context of concerns over the nexus between pharmaceutical promotion and prescribing practices, particularly where patients may ultimately bear the additional financial consequences of such decisions.
The Supreme Court is expected to consider the Centre’s proposed course of action while deciding the way forward in the matter.
The post Supreme Court asks Centre to form panel on Pharma companies offering freebies to Doctors for prescribing drugs appeared first on India Legal.